Tumour necrosis factor-alpha plasma levels in elderly patients with Type 2 diabetes mellitus - observations over 2 years
Tumour necrosis factor-alpha plasma levels in elderly patients with Type 2 diabetes mellitus - observations over 2 years
复制标题
DOI:
10.1046/j.1464-5491.2002.00846.x
复制
发表时间:
2002-11-01
影响因子:
3.5
通讯作者:
Dzien, A
中科院分区:
文献类型:
--
作者:
Lechleitner, M;Herold, M;Dzien, A
Aims The cytokine tumour necrosis factor-alpha (TNF-alpha) is involved in the development of obesity-linked insulin resistance. TNF-alpha plasma levels rise with increasing age and might thus also be related to metabolic control in Type 2 diabetes mellitus. We have studied the relationship of TNF-alpha plasma levels to glycaemic control in elderly patients with Type 2 diabetes over 2 years.Methods Clinical and laboratory data of 53 patients (26 women, 27 men) with Type 2 diabetes (mean age 71.6+/-5.6 years) were regularly evaluated over 2 years, and the relationship to anti-diabetic treatment regimens analysed. TNF-alpha plasma level was measured by a solid-phase enzyme amplified sensitivity immunoassay.Results TNF-alpha plasma levels increased significantly from 16.2+/-9.6 pg/ml at baseline to 28.0+/-13.8 pg/ml after 2 years (P=0.028). HbA(1c) values also increased from 6.4+/-1.2% to 7.7+/-1.6% (P=0.046). Mean body mass index of the patients remained almost constant, while a moderate increase in the percentage of body fat (34.5+/-7.0% to 35.3+/-6.9%; P=0.061) and in waist-hip ratio was observed (0.86+/-0.04 to 0.88+/-0.04; P=0.052). After adjustment for covariates multivariate analysis demonstrated that TNF-alpha plasma levels are positively related to the HbA(1c) values of the whole study population at the baseline control and after 2 years. TNF-alpha also revealed a positive correlation to the percentage of body fat.Conclusions In elderly patients with Type 2 diabetes TNF-alpha plasma levels revealed a continuous increase during an observation period of 2 years. This increase in TNF-alpha plasma levels might add another aspect to the worsening of glycaemic control in the progression of Type 2 diabetes.